Travere Therapeutics Provides Corporate Update and 2026 Outlook View Full Press Release Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS